Ph+ (BCR::ABL1-Positive) ALL: What to Do When TKI-Based Induction Fails to Achieve Complete Remission

Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia, confirmed by karyotyping and/or molecular genetics, is a molecularly distinct, high-risk form of ALL. When initial induction therapy does not achieve complete remission, a defined subsequent protocol applies.

Specific Clinical Situation

This protocol addresses patients with Philadelphia chromosome / BCR::ABL1-positive ALL, a diagnosis established through karyotyping and/or molecular genetic testing.

Previous Line — Induction Did Not Achieve Complete Remission

Standard first-line induction for Ph+ ALL consists of a tyrosine-kinase inhibitor — imatinib, dasatinib, nilotinib, or ponatinib — combined with steroids and often vincristine, with mandatory CNS prophylaxis. The primary goal of this induction phase is achievement of complete remission. When complete remission is not reached, this protocol defines the structured next step.

Next-Step Approach (Partial Overview)

Management after induction in this setting involves a consolidation strategy that combines a targeted agent with chemotherapy. The complete protocol — including cycle structure, agent-specific considerations, and decision points — is in the full regimen.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/blood.2023023568

Confirmation of Ph+ ALL relies on karyotyping and/or molecular genetics.

Postremission therapy is commonly initiated with 1 or 2 consolidation cycles combining a TKI with more intensive chemotherapy, analogous to treatment of Ph-negative patients; use of ASP is discouraged by some groups.

View source ↗